Sanwa Kagaku Kenkyusho Co., Ltd.

Kabushiki Kaisha Sanwa Kagaku Kenkyusho

Takahiko Mitani

Kiichi Sawai

Masayasu Kurono

Naohisa Ninomiya

Haruo Takahashi

Hiromoto Asai

Yoshiro Ishiwata

Kenichi Tanaka

Yasuaki Kondo

Takahito Jomori

Kyoichi Asano

Ryoichi Unno

Makoto Sato

Yutaka Baba

Syoji Yokochi

Hisashi Michishita

Takuji Kakigami

Hiromoto Kimura

Shunji Natori

Kazumasa Nakano

Katsuya Fujimura

Eiji Furukawa

Bunkichi Kato

Hiroyuki Ohwaki

Jun Takeda

Yasuo Suzuki

Akira Hasegawa

Toshinao Usui

Yukiharu Matsumoto

Shoji Yokochi

Masato Fukushima

Hiroshi Ozawa

Hiroo Imura

Yuji Hayashi

Akira Tashita

Toshiyuki Kouzaki

Tomoo Suzuki

Motohide Hayashi

Kaneo Yamada

Noriyuki Iwata

Yohei Kobayashi

Tunematu Suzuki

Yutaka Seino

Mikio Minamitani

Takashi Meguro

Masashi Taki

Takao Matumoto

Yuichi Shiokawa

Keizo Anzai

Masanori Nagabuchi

Kougaku Isogawa

Tamaki Ohtuka

Hiromiotu Asai

Hiroyuki Oowaki

Yoshirou Ishiwata

Takao Sugiyama

Hidetsugu Saito

Yoshiro Ishiwatari

Hitoshi Hamashima

Takao Igami

Masahiko Koketsu

Kazumi Niu

Masao Onishi

There are described sulfated and phosphated saccharide erivatives of the Formula ##STR1## wherein R.sub.1 is hydrogen atom or a residue of sulfate, phosphate or L-fucose; R.sub.2, R.sub.3 and R.sub.4 are hydrogen atom or a residue of sulfate or phosphate, respectively; 1 is an integer of 0 or 1;

Sulfated and phosphated saccharide derivatives, process for the

A potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator are provided. The potentiator is a mixture of flavin adenine dinucleotide (FAD) and porcine liver extract.

Potentiator for interferon and an antiviral activity-potentiating

A maillard reaction inhibitor comprising, as the principal component, an eight-structural polymer of 3-oxygermylpropionic acid represented by the following stereostructure (I): ##STR1## wherein R represents --CH.sub.2 CH.sub.2 COOH, and m is a weight average polymerization degree calculated on the basis of the weight average molecular weight of propagermanium propyl ester and is 137.+-.84 (137 on average with a standard deviation of .+-.3.sigma.); and having the following minimum constitutional unit:

Maillard reaction inhibitor

Wart of human being is prevented or cured by administration of a pharmaceutical composition containing an eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84.

Method of treating wart

A novel, eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84. A pharmaceutical composition containing the novel polymer is useful for preventing symptoms of an immune disease such as hepatitis or for curing such a disease.

3-oxygermylpropionic acid polymer, pharmaceutical composition containing

Process for the preparation of motilin-like polypeptide, a recombinant DNA therefor, and a plasmid, in which the recombinant DNA is inserted.

Process for the preparation of motilin-like polypeptide and expression

A readily absorbable type of motilin preparation containing a motilin-like active substance and a surface active agent is provided, in which the motilin-like active substance is mainly L-leucine-13-motilin-homoserine, and the surface active agent is selected from the group consisting of a bile salt, saponin and a polyethylene glycol higher-alcohol ether for nasal administration purposes and is a peptide lytic enzyme inhibitor for oral administration purposes.

Use of orally absorbable motilin preparations to enhance motility of

A pharmaceutical composition for stimulating peristaltic contraction in the intestinal canal which contains a pharmaceutically acceptable carrier or excipient and an effective amount of a polypeptide, or a salt thereof, having a pharmacological activity similar to motilin. The polypeptide has the formula B.sub.1 -Z.sub.1 -A.sub.1 -Z.sub.2 -B.sub.2 -Thr-B.sub.3 -A.sub.2 -Glu-Z.sub.3 -C-Arg-X'-Gln-Glu-Lys-Glu-Arg-D-Lys-Gly-E-Y, with Z.sub.1,Z.sub.2 and Z.sub.3 each being an amino acid residue having a hydrophobic side-chain, A.sub.1 and A.sub.2 each being an amino acid residue such as Pro, Gly, Asn and Ser, B.sub.1, B.sub.2 and B.sub.3 are each an amino acid residue having a side-chain with an aromatic ring, C is Gln, Glu or Asp, D is Asn, Glu or Asp, X' is an amino acid residue other than Met, E is Gln, Lys or Arg, and Y is homoserine, homoserine-lactone or a peptide chain having amino acid residues not exceeding 10 and containing homoserine or homoserine-lactone at the C-terminal where the first amino acid of said peptide chain is other than Lys, Arg or Pro.

Motlin-like polypeptide and use thereof

Vasoactive intestinal polypeptide (VIP) analogues and use thereof are disclosed. The VIP analogues are shown by the formula of

Vasoactive intestinal polypeptide analogues and use thereof

There is disclosed a pharmaceutical preparation which contains vasoactive intestinal polypeptide (VIP), its analogue or a salt thereof, and a surfactant. The preparation shall contains further a peptidase inhibitor. The composition is administrated to suppress allergies, reduce blood pressure, increase secretion of tear, cure asthma and impotence and others.

Pharmaceutical preparation containing vasoactive intestinal polypeptide

The invention provides a novel glycoside which contains as the aglycon a 4-(substituted phenyl)piperazine-1-yl derivative of glycyrrhetinic acid and 11-deoxo-glycyrrhetinic acid or their derivative as well as a composition for the treatment of virus infection, which contains these compounds as a main active component.

Glycyrrhetinic acid derivatives

A 3-oxygermylpropionic acid preparation is provided, which activates the action of 3-oxygermylpropionic acid having the general formula: [(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH]n wherein n=an integer of at least 1 and is readily solubilized and disintegrated in vivo. The present preparation is manufactured by compression-molding at high pressure a composition comprising 3-oxygermylpropionic acid and two or more low-molecular substance of high solubility in water. The low-molecular substances are selected from the group consisting of white sugar, sorbitol, fructose, sucrose, glucose, lactose, mannitol and sodium chloride.

Binder-free orally administrable tablet containing 3-oxygermylpropionic

An organic germanium compound to be effectively used for curing AIDS or making AIDS asymtomatic in various forms is expressed by the following rational formula: ##STR1## wherein n is an integer of 1 or 2 or more, is in the form of a white acicular or needle crystal, shows a solubility of 1.570/100 ml in water at 25.degree. C. and exhibits a melting (decomposition) point of 240.degree. C.

Composition for enhancing biosynthesis of interferon

A composition for inhibiting the degeneration of cells including liver cells by drugs and relieving the toxicity of drugs to internal organs including the liver contains as an essential component a 3-oxygermylpropionic acid polymer which is represented by:

Pharmaceutical composition comprising a medicament and

Pharmaceutical compositions for oral administration used for the treatment and prevention of hyperlipemia, obesity and obesity-related diseases contain phytic acid or its salt as a pharmaceutically effective component.

Pharmaceutical compositions containing phytic acid or its salts

Growing community of inventors

Nagoya, Japan

Takahiko Mitani